Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michelle F Homsher"'
Autor:
Elisabeth MacColl, Paul Zuck, Victor N. Uebele, Michelle F Homsher, Jeffrey D. Hermes, Jason Cassaday, Jennifer Nothstein
Publikováno v:
SLAS Technology. 22:485-492
Automated mechanism of action studies are introducing the need for tailored compound delivery, which can be challenging for standard compound management procedures. Jump dilution assays investigating inhibitor reversibility require compound delivery
Autor:
Douglas C. Beshore, Stephen Day, Jason Cassaday, Michelle F. Homsher, Brian Squadroni, David Pechter, Michelle Smith, Lei Ma, Jeffrey D. Hermes, Elizabeth Mohammed, Michelle Hartnett, Paul Zuck, Michael F.A. Finley, Victor N. Uebele, Fredrick Monsma
Publikováno v:
SLAS Discovery. 22:1060-1066
Agonist shift assays feature cross-titrations of allosteric modulators and orthosteric ligands. Information generated in agonist shift assays can include a modulator's effect on the orthosteric agonist's potency (alpha) and efficacy (beta), as well a
Autor:
Michelle F. Homsher, Louis Locco, Shannon L. Stahler, Michael Weber, Jennifer E. Nothstein, Eleftheria N. Finger, Evelyn Boots, Mee Ra Heo, Amita Patel, Gregory O'Donnell, Alex Wolicki, Michael F.A. Finley, J. Christopher Culberson, Paul Zuck, Juncai Meng, Kenneth Roberts, David J. Bell, Peter S. Kutchukian, Gregory C. Adam, Carissa Quinn, Patrick Cocchiarella, Meir Glick, S. Alex May, Victor N. Uebele, Edward Hudak, Brian Squadroni, Daniel Riley, Andrew Rusinko, Kelli Solly, Michelle Hartnett, Dante A. Pertusi, Adam Amoss, Anthony Kreamer, Tara White, Anne Mai Wassermann
Publikováno v:
SLAS Discovery. 22:995-1006
High-throughput screening (HTS) is a widespread method in early drug discovery for identifying promising chemical matter that modulates a target or phenotype of interest. Because HTS campaigns involve screening millions of compounds, it is often desi
Autor:
Anna Konovalova, Hao Wang, Holly A. Sutterlin, Xiaoqing Han, Smaranda Bodea, Frances P. Rodriguez-Rivera, Adam G. Schwaid, Thomas J. Silhavy, Jessica Ruolin Sheng, Todd A. Black, Terry Roemer, Elizabeth M. Hart, Marcin Grabowicz, Carl J. Balibar, Qian Si, Scott S. Walker, Deborah M. Rothman, Ronald E. Painter, Juliana C. Malinverni, Michelle F. Homsher, Angela M. Mitchell, Anthony Ogawa
The development of new antimicrobial drugs is a priority to combat the increasing spread of multidrug-resistant bacteria. This development is especially problematic in gram-negative bacteria due to the outer membrane (OM) permeability barrier and mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d37bc56f3a1463af9d150c6c6855d4a
https://europepmc.org/articles/PMC6815139/
https://europepmc.org/articles/PMC6815139/
Autor:
Michelle F, Homsher, Douglas C, Beshore, Jason, Cassaday, Brian, Squadroni, Elizabeth, Mohammed, Michelle, Hartnett, Stephen, Day, Lei, Ma, David, Pechter, Michelle D, Smith, Fredrick, Monsma, Paul, Zuck, Michael F, Finley, Victor N, Uebele, Jeffrey D, Hermes
Publikováno v:
SLAS discovery : advancing life sciences RD. 22(8)
Agonist shift assays feature cross-titrations of allosteric modulators and orthosteric ligands. Information generated in agonist shift assays can include a modulator's effect on the orthosteric agonist's potency (alpha) and efficacy (beta), as well a